orion pharma (uk) limited Company Information
Company Number
02281057
Next Accounts
Sep 2025
Shareholders
orion corporation
Group Structure
View All
Industry
Wholesale of pharmaceutical goods
Registered Address
the scalpel, 18th floor, 52 lime street, london, EC3M 7AF
Website
www.orionpharma.co.ukorion pharma (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of ORION PHARMA (UK) LIMITED at £24.8m based on a Turnover of £25.4m and 0.98x industry multiple (adjusted for size and gross margin).
orion pharma (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of ORION PHARMA (UK) LIMITED at £14.2m based on an EBITDA of £1.5m and a 9.71x industry multiple (adjusted for size and gross margin).
orion pharma (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of ORION PHARMA (UK) LIMITED at £26m based on Net Assets of £13.6m and 1.91x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Orion Pharma (uk) Limited Overview
Orion Pharma (uk) Limited is a live company located in london, EC3M 7AF with a Companies House number of 02281057. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in July 1988, it's largest shareholder is orion corporation with a 100% stake. Orion Pharma (uk) Limited is a mature, large sized company, Pomanda has estimated its turnover at £25.4m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Orion Pharma (uk) Limited Health Check
Pomanda's financial health check has awarded Orion Pharma (Uk) Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
![Health Check Image](/assets/images/big_heart.png)
![positive_score](/assets/images/scoreRate2.png)
6 Strong
![positive_score](/assets/images/scoreRate1.png)
1 Regular
![positive_score](/assets/images/scoreRate0.png)
4 Weak
![size](/assets/images/scoreRate1.png)
Size
annual sales of £25.4m, make it in line with the average company (£24.7m)
£25.4m - Orion Pharma (uk) Limited
£24.7m - Industry AVG
![growth](/assets/images/scoreRate2.png)
Growth
3 year (CAGR) sales growth of 13%, show it is growing at a faster rate (5.3%)
13% - Orion Pharma (uk) Limited
5.3% - Industry AVG
![production](/assets/images/scoreRate2.png)
Production
with a gross margin of 40.8%, this company has a lower cost of product (29.5%)
40.8% - Orion Pharma (uk) Limited
29.5% - Industry AVG
![profitability](/assets/images/scoreRate2.png)
Profitability
an operating margin of 5.8% make it more profitable than the average company (4.1%)
5.8% - Orion Pharma (uk) Limited
4.1% - Industry AVG
![employees](/assets/images/scoreRate2.png)
Employees
with 48 employees, this is above the industry average (36)
48 - Orion Pharma (uk) Limited
36 - Industry AVG
![paystructure](/assets/images/scoreRate0.png)
Pay Structure
on an average salary of £121.2k, the company has a higher pay structure (£81.8k)
£121.2k - Orion Pharma (uk) Limited
£81.8k - Industry AVG
![efficiency](/assets/images/scoreRate0.png)
Efficiency
resulting in sales per employee of £528.9k, this is less efficient (£673.7k)
£528.9k - Orion Pharma (uk) Limited
£673.7k - Industry AVG
![debtordays](/assets/images/scoreRate0.png)
Debtor Days
it gets paid by customers after 91 days, this is later than average (58 days)
91 days - Orion Pharma (uk) Limited
58 days - Industry AVG
![creditordays](/assets/images/scoreRate0.png)
Creditor Days
its suppliers are paid after 9 days, this is quicker than average (29 days)
9 days - Orion Pharma (uk) Limited
29 days - Industry AVG
![stockdays](/assets/images/scoreRate-1.png)
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Orion Pharma (uk) Limited
- - Industry AVG
![cashbalance](/assets/images/scoreRate2.png)
Cash Balance
has cash to cover current liabilities for 22 weeks, this is more cash available to meet short term requirements (11 weeks)
22 weeks - Orion Pharma (uk) Limited
11 weeks - Industry AVG
![debtlevel](/assets/images/scoreRate2.png)
Debt Level
it has a ratio of liabilities to total assets of 23.7%, this is a lower level of debt than the average (54%)
23.7% - Orion Pharma (uk) Limited
54% - Industry AVG
ORION PHARMA (UK) LIMITED financials
![ms excel logo](/assets/images/ms_excel_logo.png)
Orion Pharma (Uk) Limited's latest turnover from December 2023 is £25.4 million and the company has net assets of £13.6 million. According to their latest financial statements, Orion Pharma (Uk) Limited has 48 employees and maintains cash reserves of £1.8 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 25,387,050 | 22,240,127 | 17,052,459 | 17,811,320 | 16,807,148 | 17,935,129 | 19,194,297 | 19,369,961 | 21,652,905 | 23,826,324 | 26,023,604 | 27,309,249 | 27,776,860 | 25,419,513 | 22,160,023 |
Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cost Of Sales | 15,017,423 | 14,250,215 | 11,032,046 | 12,084,482 | 9,832,453 | 10,734,186 | 12,775,749 | 13,082,953 | 14,856,164 | 16,283,533 | 17,634,340 | 18,407,007 | 18,895,313 | 16,169,541 | |
Gross Profit | 10,369,627 | 7,989,912 | 6,020,413 | 5,726,838 | 6,974,695 | 7,200,943 | 6,418,548 | 6,287,008 | 6,796,741 | 7,542,791 | 8,389,264 | 8,902,242 | 8,881,547 | 9,249,972 | |
Admin Expenses | 8,905,074 | 6,844,838 | 5,320,050 | 4,916,751 | 6,426,919 | 7,014,636 | 5,553,855 | 4,938,339 | 5,405,443 | 4,661,444 | 4,967,452 | 5,137,149 | 5,331,834 | 4,517,322 | |
Operating Profit | 1,464,553 | 1,145,074 | 700,363 | 810,087 | 547,776 | 186,307 | 864,693 | 1,348,669 | 1,391,298 | 2,881,347 | 3,421,812 | 3,765,093 | 3,549,713 | 4,732,650 | 5,373,987 |
Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 296 | 910 |
Interest Receivable | 459,260 | 55,918 | 32,050 | 95,711 | 122,515 | 75,339 | 46,135 | 132,387 | 158,616 | 123,413 | 149,535 | 358,558 | 240,835 | 149,198 | 200,454 |
Pre-Tax Profit | 1,923,813 | 1,200,992 | 732,413 | 905,798 | 670,291 | 261,646 | 910,828 | 1,481,056 | 1,549,914 | 3,004,760 | 3,571,345 | 4,123,651 | 3,790,548 | 4,881,552 | 5,573,531 |
Tax | -491,564 | -246,591 | -153,491 | -190,490 | -140,670 | -88,500 | -188,777 | -320,697 | -405,721 | -568,822 | -765,695 | -954,673 | -991,355 | -1,348,455 | 508,404 |
Profit After Tax | 1,432,249 | 954,401 | 578,922 | 715,308 | 529,621 | 173,146 | 722,051 | 1,160,359 | 1,144,193 | 2,435,938 | 2,805,650 | 3,168,978 | 2,799,193 | 3,533,097 | 6,081,935 |
Dividends Paid | 4,000,000 | 4,000,000 | 4,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Profit | -2,567,751 | -3,045,599 | -3,421,078 | 715,308 | 529,621 | 173,146 | 722,051 | 1,160,359 | 1,144,193 | 2,435,938 | 2,805,650 | 3,168,978 | 2,799,193 | 3,533,097 | 6,081,935 |
Employee Costs | 5,815,678 | 4,864,225 | 4,613,932 | 4,303,306 | 4,132,731 | 4,175,722 | 3,993,307 | 3,839,280 | 3,807,151 | 3,795,934 | 4,033,661 | 4,202,286 | 4,045,099 | 4,018,932 | 3,856,243 |
Number Of Employees | 48 | 50 | 47 | 46 | 45 | 48 | 48 | 44 | 46 | 47 | 55 | 58 | 59 | 60 | 60 |
EBITDA* | 1,465,238 | 1,154,127 | 702,802 | 814,089 | 553,515 | 193,226 | 871,832 | 1,353,987 | 1,396,894 | 2,894,950 | 3,436,607 | 3,780,319 | 3,580,940 | 4,790,398 | 5,483,042 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 971 | 1,656 | 2,341 | 4,780 | 8,782 | 14,521 | 21,440 | 27,229 | 21,742 | 9,148 | 16,248 | 30,668 | 35,906 | 44,183 | 91,494 |
Intangible Assets | 92,049 | 117,154 | 47,930 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 7,101,856 | 7,101,856 | 7,101,856 | 7,101,856 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 20,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 93,020 | 118,810 | 50,271 | 4,780 | 20,008,782 | 14,521 | 7,123,296 | 7,129,085 | 7,123,598 | 7,111,004 | 16,248 | 30,668 | 35,906 | 44,183 | 91,494 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Debtors | 6,345,529 | 4,655,556 | 4,195,132 | 3,379,790 | 3,051,713 | 3,492,318 | 4,027,786 | 4,061,164 | 4,008,665 | 4,589,896 | 5,160,487 | 5,485,387 | 5,807,328 | 5,194,123 | 3,881,429 |
Group Debtors | 9,362,426 | 11,705,999 | 870,966 | 721,654 | 258,187 | 292,476 | 923,315 | 768,952 | 19,866,434 | 18,674,468 | 22,929,853 | 20,255,011 | 16,532,237 | 14,393,323 | 8,695,157 |
Misc Debtors | 169,639 | 221,765 | 259,268 | 355,566 | 375,907 | 384,901 | 474,579 | 353,093 | 245,701 | 287,217 | 367,302 | 352,607 | 458,212 | 1,379,469 | 2,622,707 |
Cash | 1,845,356 | 2,432,079 | 17,961,445 | 22,424,105 | 1,275,157 | 29,526,911 | 21,679,465 | 21,786,219 | 1,718,273 | 1,111,660 | 1,032,374 | 683,253 | 763,050 | 576,281 | 625,344 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 17,722,950 | 19,015,399 | 23,286,811 | 26,881,115 | 4,960,964 | 33,696,606 | 27,105,145 | 26,969,428 | 25,839,073 | 24,663,241 | 29,490,016 | 26,776,258 | 23,560,827 | 21,543,196 | 15,824,637 |
total assets | 17,815,970 | 19,134,209 | 23,337,082 | 26,885,895 | 24,969,746 | 33,711,127 | 34,228,441 | 34,098,513 | 32,962,671 | 31,774,245 | 29,506,264 | 26,806,926 | 23,596,733 | 21,587,379 | 15,916,131 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 379,499 | 233,305 | 196,535 | 280,069 | 35,430 | 135,138 | 171,181 | 83,596 | 91,465 | 104,118 | 75,433 | 86,649 | 155,433 | 211,396 | 120,200 |
Group/Directors Accounts | 1,714,096 | 453,920 | 2,348,577 | 2,609,812 | 807,676 | 362,912 | 1,366,019 | 1,406,409 | 1,387,983 | 1,498,251 | 1,922,128 | 1,789,950 | 2,121,153 | 3,136,824 | 1,021,915 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 2,121,496 | 2,340,355 | 1,694,742 | 1,521,208 | 1,290,142 | 1,434,200 | 1,163,510 | 1,802,828 | 1,837,902 | 1,670,748 | 1,442,633 | 1,654,347 | 1,197,542 | 900,187 | 952,582 |
total current liabilities | 4,215,091 | 3,027,580 | 4,239,854 | 4,411,089 | 2,133,248 | 1,932,250 | 2,700,710 | 3,292,833 | 3,317,350 | 3,273,117 | 3,440,194 | 3,530,946 | 3,474,128 | 4,248,407 | 2,094,697 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 880 | 16,440 | 32,043 | 47,603 | 63,162 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 880 | 16,440 | 32,043 | 47,603 | 63,162 |
total liabilities | 4,215,091 | 3,027,580 | 4,239,854 | 4,411,089 | 2,133,248 | 1,932,250 | 2,700,710 | 3,292,833 | 3,317,350 | 3,273,117 | 3,441,074 | 3,547,386 | 3,506,171 | 4,296,010 | 2,157,859 |
net assets | 13,600,879 | 16,106,629 | 19,097,228 | 22,474,806 | 22,836,498 | 31,778,877 | 31,527,731 | 30,805,680 | 29,645,321 | 28,501,128 | 26,065,190 | 23,259,540 | 20,090,562 | 17,291,369 | 13,758,272 |
total shareholders funds | 13,600,879 | 16,106,629 | 19,097,228 | 22,474,806 | 22,836,498 | 31,778,877 | 31,527,731 | 30,805,680 | 29,645,321 | 28,501,128 | 26,065,190 | 23,259,540 | 20,090,562 | 17,291,369 | 13,758,272 |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||||
Operating Profit | 1,464,553 | 1,145,074 | 700,363 | 810,087 | 547,776 | 186,307 | 864,693 | 1,348,669 | 1,391,298 | 2,881,347 | 3,421,812 | 3,765,093 | 3,549,713 | 4,732,650 | 5,373,987 |
Depreciation | 685 | 9,053 | 2,439 | 4,002 | 5,739 | 6,919 | 7,139 | 5,318 | 5,596 | 13,603 | 14,795 | 15,226 | 31,227 | 57,748 | 109,055 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | -491,564 | -246,591 | -153,491 | -190,490 | -140,670 | -88,500 | -188,777 | -320,697 | -405,721 | -568,822 | -765,695 | -954,673 | -991,355 | -1,348,455 | 508,404 |
Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors | -705,726 | 11,257,954 | 868,356 | -19,228,797 | 19,516,112 | -1,255,985 | 242,471 | -18,937,591 | 569,219 | -4,906,061 | 2,364,637 | 3,295,228 | 1,830,862 | 5,767,622 | 15,199,293 |
Creditors | 146,194 | 36,770 | -83,534 | 244,639 | -99,708 | -36,043 | 87,585 | -7,869 | -12,653 | 28,685 | -11,216 | -68,784 | -55,963 | 91,196 | 120,200 |
Accruals and Deferred Income | -218,859 | 645,613 | 173,534 | 231,066 | -144,058 | 270,690 | -639,318 | -35,074 | 167,154 | 227,235 | -227,274 | 441,202 | 281,795 | -67,954 | 1,015,744 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | 1,606,735 | -9,668,035 | -229,045 | 20,328,101 | -19,347,033 | 1,595,358 | -111,149 | 19,927,938 | 576,455 | 7,488,109 | 67,785 | -97,164 | 984,555 | -2,302,437 | -8,071,903 |
Investing Activities | |||||||||||||||
capital expenditure | |||||||||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | -7,101,856 | 0 | 0 | 0 | 7,101,856 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||||||||||||
Financing Activities | |||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 1,260,176 | -1,894,657 | -261,235 | 1,802,136 | 444,764 | -1,003,107 | -40,390 | 18,426 | -110,268 | -423,877 | 132,178 | -331,203 | -1,015,671 | 2,114,909 | 1,021,915 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | |||||||||||||||
interest | 459,260 | 55,918 | 32,050 | 95,711 | 122,515 | 75,339 | 46,135 | 132,387 | 158,616 | 123,413 | 149,533 | 358,558 | 240,835 | 148,902 | 199,544 |
cash flow from financing | 1,781,437 | -1,783,739 | -185,685 | 820,847 | -8,904,721 | -849,768 | 5,745 | 150,813 | 48,348 | -300,464 | 281,711 | 27,355 | -774,836 | 2,263,811 | 8,897,796 |
cash and cash equivalents | |||||||||||||||
cash | -586,723 | -15,529,366 | -4,462,660 | 21,148,948 | -28,251,754 | 7,847,446 | -106,754 | 20,067,946 | 606,613 | 79,286 | 349,121 | -79,797 | 186,769 | -49,063 | 625,344 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -586,723 | -15,529,366 | -4,462,660 | 21,148,948 | -28,251,754 | 7,847,446 | -106,754 | 20,067,946 | 606,613 | 79,286 | 349,121 | -79,797 | 186,769 | -49,063 | 625,344 |
orion pharma (uk) limited Credit Report and Business Information
Orion Pharma (uk) Limited Competitor Analysis
![competitor_analysis_table_img](/assets/images/competitor_analysis_table.png)
Perform a competitor analysis for orion pharma (uk) limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in EC3M area or any other competitors across 12 key performance metrics.
orion pharma (uk) limited Ownership
ORION PHARMA (UK) LIMITED group structure
Orion Pharma (Uk) Limited has no subsidiary companies.
Ultimate parent company
ORION CORP
#0025301
1 parent
ORION PHARMA (UK) LIMITED
02281057
orion pharma (uk) limited directors
Orion Pharma (Uk) Limited currently has 3 directors. The longest serving directors include Mr Olli Houtari (May 2007) and Dr Aino Hurme (Jan 2023).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Olli Houtari | United Kingdom | 58 years | May 2007 | - | Director |
Dr Aino Hurme | Finland | 57 years | Jan 2023 | - | Director |
Mr Rene Lindell | United Kingdom | 48 years | Apr 2024 | - | Director |
P&L
December 2023turnover
25.4m
+14%
operating profit
1.5m
+28%
gross margin
40.9%
+13.7%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
13.6m
-0.16%
total assets
17.8m
-0.07%
cash
1.8m
-0.24%
net assets
Total assets minus all liabilities
orion pharma (uk) limited company details
company number
02281057
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
July 1988
age
37
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
deprenyl research limited (May 1995)
accountant
-
auditor
JAMES COWPER KRESTON AUDIT LLP
address
the scalpel, 18th floor, 52 lime street, london, EC3M 7AF
Bank
DANSKE BANK AS
Legal Advisor
CHARLES RUSSELL
orion pharma (uk) limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to orion pharma (uk) limited. Currently there are 2 open charges and 0 have been satisfied in the past.
orion pharma (uk) limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ORION PHARMA (UK) LIMITED. This can take several minutes, an email will notify you when this has completed.
orion pharma (uk) limited Companies House Filings - See Documents
date | description | view/download |
---|